Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar whomonkyoulus (28.88) Submitted: 12/8/2010 7:00:06 PM : Outperform Start Price: $57.02 CELG Score: +14.94

Perfect

Featured Broker Partners


Advertisement